Session VIII: Indolent Lymphomas and CAR-T Cells

Moderator(s)

• 

  Samuel Yamshon, MD

  Weill Cornell Medicine
  New York, New York, United States

Presenter(s)

• 

  Nancy Bartlett, MD

  Washington University
  St. Louis, Missouri, United States
• 

  Morie Gertz, MD, MACP

  Mayo clinic
  Rochester, Minnesota, United States
• 

  Caron Jacobson, MD, MMSc

  Medical Oncology
  Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts, United States

Talks in this session are supported by an educational grant from Pharmacyclics, an Abbvie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs, LLC.

Presentations:

• 4:00 PM – 4:05 PM ET

  Pre-Session Audience Survey
• 4:05 PM – 4:25 PM ET

  The Bruce Waterfall Memorial Lecture: When to Treat Waldenstrom’s Macroglobulinemia? How to Sequence Medicine
  

  Speaker: Morie A. Gertz, MD, MACP – Mayo clinic
• 4:25 PM – 4:40 PM ET

  Debate: Patients with Recurrent Follicular Lymphoma Should Receive CAR-T Cells vs Bispecific Antibodies - CAR-T CELLS
  

  Debate Speaker: Caron A. Jacobson, MD, MMSc – Dana-Farber Cancer Institute, Harvard Medical School
• 4:40 PM – 4:55 PM ET

  Debate: Patients with Recurrent Follicular Lymphoma Should Receive CAR-T Cells vs Bispecific Antibodies - BISPECIFIC ANTIBODIES
  

  Debate Speaker: Nancy L. Bartlett, MD – Washington University
• 4:55 PM – 5:15 PM ET

  CAR-T cells – What does the Future Hold? Are all CAR-Ts Comparable?
  

  Speaker: Caron A. Jacobson, MD, MMSc – Dana-Farber Cancer Institute, Harvard Medical School
• 5:15 PM – 5:35 PM ET

  Panel Discussion and Post-Session Audience Survey
  

  Panelist: Nancy L. Bartlett, MD – Washington University

  Panelist: Morie A. Gertz, MD, MACP – Mayo clinic

  Panelist: Caron A. Jacobson, MD, MMSc – Dana-Farber Cancer Institute, Harvard Medical School